1. Introduction
===============

Despite rigorous controls being applied to biotechnology production processes, contamination with viruses is a common feature in most of the biological products. Viral contamination of a biological may occur from the source material, e.g. cell banks of animal origin, human blood, human or animal tissues, or as adventitious agents introduced by the production process, e.g. the use of animal sera in mammalian cell culture.

It is for this reason that process validation becomes an important tool for evaluating biopharmaceutical production processes of any mammalian-derived product. The virus validation should provide a high level of assurance that final product will be free of contaminants.

This kind of study involves spiking the scale down downstream process with a highly infectious virus titer and evaluating the removal/inactivation ability of the whole process or process steps to reduce viruses.

It is not necessary to validate every individual step of a given manufacturing process, only those steps which most likely contribute to inactivate/remove any virus need to be subject to a validation study ([@BIB9]).

Model or relevant viruses need to be evaluated and these should represent the potential viral contaminants in the starting material ([Table 1](#TBL1){ref-type="table"} ).Table 1Main viral agents potentially present in murine hybridomas, mice and ratsVirusGenomeEnvelopeSize (nm)Target systemHantaan and related virusesRNAYes80--160MultipleSendaiRNAYes100--200RespiratoryLymphocytic ChoriomeningitisRNAYes60--280HemopoieticReovirus type 3RNANo75--80DigestiveRotavirusRNANo70--75DigestiveMinute virus of miceDNANo20--25MultipleEctromeliaDNANo175--290Skin and jointsK virusDNANo35--45Respiratory*Polyomavirus muris* 1DNANo45MultipleMouse thymic virusDNAYes125--165DigestivePneumonia virus of miceRNAYes80--200RespiratoryLactate DH elevating virusRNAYes50--55HemopoieticMouse adenovirusDNAYes70--90DigestiveMouse hepatitisRNAYes80--160DigestiveMouse encephalomyelitisRNANo28--30Central NervousMurine cytomegalovirusDNAYes120--200DigestiveToolanDNANo18--30MultipleRat coronavirus/SialodacryoadenitisRNAYes60--200DigestiveKilham rat virusDNANo18--30Multiple[^1]

Another critical element into the viral validation process is the validity of the scale down, which can be demonstrated by comparison of process parameters such as pH, temperature and bioseparation variables (e.g. residence time, elution profile, specific activity etc.).

Due to the risk of viral contamination the virus validation study should be performed in a laboratory physically separated from the large-scale production facilities.

In this work we have studied the clearance factor of protein A affinity chromatography, acid pH and a combination of high temperature with a chaotropic agent for the production of a recombinant hepatitis B virus vaccine.

2. Materials and methods
========================

2.1. Monoclonal antibody CB.Hep-1
---------------------------------

The monoclonal antibody (Mab) CB.Hep-1 is an IgG~2b~, specific for the 'a' determinant of the recombinant hepatitis B surface antigen (rHBsAg) ([@BIB5]). This Mab is used as immunoligand in the downstream purification process of rHBsAg, which is employed for a commercially available recombinant hepatitis B virus vaccine (HeberBiovac HB™, Heber Biotec SA, Cuba) ([@BIB11], [@BIB2]).

The ascites was obtained from specific pathogens free BALB/c mice, which were previously submitted to rigorous microbiological controls viral infection in the ICLAS Reference Center for Rodents Viruses of Nijmegen, Holland.

The design proposed for the purification of the monoclonal antibody CB.Hep-1 was a combination of several steps including its selective purification by protein A affinity chromatography ([Fig. 1](#FIG1){ref-type="fig"} ).Fig. 1Purification of the monoclonal antibody CB.Hep-1 and its connection with the rHBsAg purification process.

2.2. Recombinant hepatitis B surface antigen
--------------------------------------------

The rHBsAg was obtained as previously described ([@BIB7]). Briefly, the recombinant *Pichia pastoris* yeast strain was kept under carefully controlled multiplication conditions.

After harvesting, the yeast cells were disrupted ([@BIB10]) to recover and purify the rHBsAg by a series of well-established steps. These included acid precipitation ([@BIB10]), adsorption/desorption from diatomaceous earth matrix ([@BIB1]) and finally, successive purification through immunoaffinity, ion exchange and gel-filtration chromatographic procedures ([@BIB1], [@BIB12]).

2.3. Virus clearance studies
----------------------------

The clearance studies were performed in a laboratory separated from the production facilities, scaling down three steps potentially able to remove and/or inactivate viral charges: protein A affinity chromatography, low pH treatment and heating at 60 °C in presence of 3 M KSCN, pH 7.0.

The virus reduction factor (*R*) was calculated individually and according to the following formula:R=logV1C1V2C2where, *V* ~1~ and *V* ~2~ are the volumes of the starting and post-processing material, respectively, and *C* ~1~ and *C* ~2~ are the virus concentrations in the starting and post-processing material, respectively. The overall clearance factor was calculated as the sum of each individual removal and inactivation factor ([@BIB6]).

The model viruses used in this viral validation study (HIV-IIIb), human herpesvirus I, canine parvovirus, human poliovirus type II and sendaivirus (see [Table 2](#TBL2){ref-type="table"} ) cover a wide range of physical--chemical and structural characteristics of the murine viruses according to the regulatory agencies recommendations ([@BIB3], [@BIB8]).Table 2Characteristics of the model viruses used in the validation studyVirusFamilyGenomeEnvelopeSize (nm)Resistance[a](#TBLFN1){ref-type="table-fn"}Human herpesvirus IHerpesviridaeDNAYes120LowCanine parvovirusParvoviridaeDNANo18--24Very highHuman poliovirus type IIPolioviridaeRNANo25--30MediumHIV-IIIbRetroviridaeRNAYes100--200LowSendaivirusParamyxoviridaeRNAYes100--200Low[^2]

### 2.3.1. Cytopathic effect

The cytopathic effect was determined by the value of the tissue culture infectious dose (*D* ~50~ ml^−1^), which was calculated following the Reed Muench method ([@BIB13]). The sensitivity limit of this assay is 10^1,3^ TCID~50~ ml^−1^. Eight experimental determinations per each of the three replies of the reduction and inactivation experiments were used as a criterion in the assays. The cell lines used (HIV negative MT4, Vero and MDK LFKB) were cultured in serum containing medium 5% CO~2~ at 37 °C for several days according to the time needed by each virus to express its cytopathic effect. All cell culture materials and reagents used in these assays came from Gibco, Grand Island, USA.

### 2.3.2. Virus removal in the protein A affinity chromatography step

In [Table 3](#TBL3){ref-type="table"} we show the parameters considered in the scale down of the protein A affinity chromatography step. We determined the purity of the eluted Mab (SDS-PAGE), the process yield and the 'specific activity' of the Mab (ELISA). These were the principal comparative criteria to define process reproducibility. The protocols of these assays have been previously described ([@BIB14]).Table 3Parameters considered in the scale down of the Mab CB.Hep-1 production processParametersLarge scaleLaboratory scaleInitial volume5--6 l50 mlLinear flow rate42 cm h^−1^42 cm h^−1^Column capacity20 mg IgG ml^−1^20 mg IgG ml^−1^High5 cm5 cmResidence time0.1 h0.1 hIgG applied90% of column capacity90% of column capacityTemperature4 °C4 °CAdsorption buffer150 mM phosphate, pH 8.0150 mM phosphate, pH 8.0Elution buffer100 mM citric acid, pH 3.0100 mM citric acid, pH 3.0

Fifty ml of semipurified material was individually loaded with viruses and applied into protein A affinity column (2.5 ml) (Amersham-Pharmacia Biotech, Upssala, Sweden) packed in a c 9/10 column, previously equilibrated with 150 mM phosphate buffer, pH 8.0. Subsequently the matrix was washed with the same buffer and the Mab CB.Hep-1 was eluted with 100 mM citric acid, pH 3.0. The samples were neutralized by addition of 2 M tris before measuring the virus cytopathic effect.

Depending on the maximum titer obtained for each virus we applied different quantities of viruses to the above mentioned column for virus removal evaluation. The initial titer was 8.4, 5.7, 7.5, 10.2 and 9.7 for sendaivirus, HIV-IIIb, human herpesvirus I, human poliovirus type II and canine parvovirus, respectively.

### 2.3.3. Virus inactivation during incubation at low pH

The viral inactivation at low pH study was carried out by incubating the samples of Mab CBV.Hep-1 containing virus at 4 °C for 7 h in 100 mM citric acid, pH 3.0 and taking samples every hour. The samples were neutralized by addition of 2 M tris to check the cytopathic effect for each virus. The initial titer was 8.0, 5.8, 9.0, 11 and 9.8 for sendaivirus, HIV-IIIb, human herpesvirus I, human poliovirus type II and canine parvovirus, respectively.

### 2.3.4. Virus inactivation during heating at 60 °C

Each virus model was inoculated in 1 ml of the eluted antigen and was incubated at 60 °C for 2 h. After this, temperature was reduced to 20 °C and the cytopathic effect was measured for each virus. The initial titer was 7.5, 5.5, 8.0, 10 and 8.5 for sendaivirus, HIV-IIIb, human herpesvirus I, human poliovirus type II and canine parvovirus, respectively.

3. Results and discussion
=========================

3.1. Virus removal in the protein A affinity chromatography step
----------------------------------------------------------------

We measured viruses by detecting their cytopathic effects (including parvo and poliovirus). This method has the disadvantage that it is culture specific-infectivity and/or replication and the effect depends on the specific virus strain; but it is quantitative, has a broad range of specificity and can detect low levels of viral contamination.

As is shown in [Table 4](#TBL4){ref-type="table"} the process yield, purity and specific activity of the Mab obtained at laboratory scale were similar to the results obtained at large scale.Table 4Efficiency of the protein A affinity chromatography scale downScaleYield (mg ml^−1^)Purity (%)SA[a](#TBLFN2){ref-type="table-fn"} (%)Large scale (20 batches)1.5\>9570--100Laboratory scale (five replicates)1.698100[^3][^4]

We evaluated the ability of the protein A affinity chromatography to remove the model viruses previously showed in [Table 2](#TBL2){ref-type="table"}. The distribution of the viral amounts onto the column is shown in [Table 5](#TBL5){ref-type="table"} .Table 5Distribution of the viral charges onto the protein A affinity chromatographic columnVirus typeInitial titer (log)Non bound titer (LRV)Elution titer (LRV)Sendaivirus8.47.20HIV-IIIb5.75.30Human herpesvirus I7.57.30Human poliovirus type II10.27.45.2Canine parvovirus9.75.94.4[^5]

Due to the specific interaction between protein A and Mab, the matrix was able to remove 86% for sendaivirus, 93% for HIV-IIIb and 97.3% for human herpesvirus I of the respective initial viral charges. It had been hypothesized that charged regions of the viral envelope would interact with protein A media. These high reduction factors coincide with results reported by other authors ([@BIB4]).

Additionally nonenveloped viruses behaved differently than the enveloped viruses. The observed reduction factor was about 71 and 60.1% for human poliovirus type II and canine parvovirus, respectively.

The behavior of nonenveloped viruses can not be explained solely by the hypothesis that certain kind of viruses could interact with the matrix by mean of electrostatic binding of positive charges present in viral enveloped glycoproteins. These results seem to suggest that the chromatographic matrix could also function as a gel filtration matrix. This is possible, because viruses ranging from 18 to 30 nm are trapped in the Sepharose CL-4B and consequently a few viral particles may not be easily removed from the inner of the solid phase. The increase in the quantity of washing buffer prior the elution step to differentiate any unspecific elution from the Mab elution could solve this problem.

In addition, we did not find inactivation of any virus into the chromatographic column. That is an important observation, because it forces us to use acid pH as an inactivating agent after the protein A affinity chromatography. As a consequence, the removal and inactivation factors obtained in the affinity and acid pH steps, respectively, can be analyzed individually, because they work under different mechanisms, which increase the cumulative clearance factor of the whole purification process. However, a longer residence time (more than 7 min) could favor the inactivation process inside the column, allowing both processes (removal and inactivation) to be considered as individual steps in terms of the cumulative process clearance factor.

3.2. Virus inactivation during incubation at low pH
---------------------------------------------------

Considering the results obtained for human poliovirus type II and canine parvovirus and also because, no single chromatographic step should be considered sufficient as its own, an additional inactivation step was included. We included the low pH condition, which occurs as part of the purification process, during the elution step (see [Fig. 1](#FIG1){ref-type="fig"}).

As [Fig. 2](#FIG2){ref-type="fig"} (I-A, II-A) illustrates almost all the initial charge of enveloped viruses was completely inactivated by pH 3.0, 75% of inactivation factor was obtained for canine parvovirus and no inactivation was demonstrated for human poliovirus type II after 7 h.Fig. 2Virus inactivation curves at low pH (A) and under heat treatment (B) using enveloped (I-A and I-B) and non-enveloped viruses (II-A and II-B), respectively. Positive control (C+): Virus under non-inactivation condition at 4 °C. These values represent the mean of three replicates. LRV. Log reduction value.

The difference observed in resistance between viruses could be partially explained, because of the presence of the viral envelope.

3.3. Virus inactivation during heating at 60 °C
-----------------------------------------------

As it was previously mentioned the purified Mab CB.Hep-1 is used during the immunopurification of rHBsAg, which is eluted from immunoaffinity column, by using 3 M KSCN.

The HBsAg that is initially liberated from yeast cells is a non-disulfide-bonded aggregate of monomer subunits. This aggregated can be converted into fully disulfide-bonded particles that resemble the natural HBsAg by treatment with 3 M KSCN, which is suggested to facilitate exchange (intrachain to interchain) within already oxidized HBsAg polypeptides ([@BIB15]), intrachain and interchain disulfide linkages between dimmers and higher multimers are known to be responsible for stabilizing the correct three-dimensional structure of highly immunogenic HBsAg particles.

As the stability of rHBsAg is increased at high concentration of 3 M KSCN, we combined this condition with high temperature (60 °C) and virus inactivation was analyzed using a phase exponential decay model.

Taking into account this process design, we carried out the spiking experiments by infecting samples with viral charges before heating them and then we evaluated viral reduction after sample desalting. As [Fig. 2](#FIG2){ref-type="fig"} (I-B, II-B) shows that 100% of the viral charges were inactivated under this condition during 60 min.

4. Conclusions
==============

Considering these results it is possible to conclude that the protein A affinity chromatography followed by a low pH treatment is able to reduce 16 logs for enveloped viruses. However, no more than 7.7 logs was the maximum clearance factor showed by these two steps for nonenveloped viruses. Human poliovirus type II was not inactivated by citric acid, pH 3.0. The heat treatment is an additional safety level, offering a robust reduction factor to the production of the Cuban hepatitis B virus vaccine.
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[^1]: Adapted from: Infectious Diseases of Mice and Rats. National Academy Press. Committee on Infectious Disease of Mice and Rats. Institute of Laboratory Animal Resources. Commission on Life Science. National Research Council.

[^2]: Resistance to physicochemical treatment.

[^3]: These values represent the mean of three independent determinations

[^4]: Specific activity (SA): Specific activity of Mab CB.Hep-1 ELISA/total proteins.

[^5]: LRV, log reduction value. The sensitivity limit of the assay is 10^1.3^ TCID~50~ ml^−1^.
